Outcomes in patients with viral infections
| UPN . | Donor . | Day of CTL . | Active viral infections . | Treatment . | Time to viral clearance after treatment (or diagnosis), wk . |
|---|---|---|---|---|---|
| 1216 | MUD | 104 | EBV BK virus | CTL None | 4-616 (after diagnosis) |
| 1217 | MUD | 150 | EBV Adv | CTL CTL | 6 2 |
| 1218 | MUD | 134 | EBV BK virus | CTL None | 2 16 (after diagnosis) |
| 1244 | HAPLO | 77 | CMV VZV | Ganciclovir Acyclovir | 3 6 |
| 1252 | MUD | 53 | HSV Parainfluenza | Acyclovir None | 16 8 (after diagnosis) |
| 1265 | MUD | 80 | BK virus | None | Unknown; positive > 4 (after diagnosis) |
| 1287 | MUD | 40 | BK virus | None | Unknown; positive > 4 (after diagnosis) |
| 1352 | HAPLO | 95 | Adv | CTL | 4 |
| 1358 | HAPLO | 86 | CMV | Foscarnet | 12 |
| 1377 | HAPLO | 77 | CMV Parainfluenza | Foscarnet None | 8 3 (after diagnosis) |
| UPN . | Donor . | Day of CTL . | Active viral infections . | Treatment . | Time to viral clearance after treatment (or diagnosis), wk . |
|---|---|---|---|---|---|
| 1216 | MUD | 104 | EBV BK virus | CTL None | 4-616 (after diagnosis) |
| 1217 | MUD | 150 | EBV Adv | CTL CTL | 6 2 |
| 1218 | MUD | 134 | EBV BK virus | CTL None | 2 16 (after diagnosis) |
| 1244 | HAPLO | 77 | CMV VZV | Ganciclovir Acyclovir | 3 6 |
| 1252 | MUD | 53 | HSV Parainfluenza | Acyclovir None | 16 8 (after diagnosis) |
| 1265 | MUD | 80 | BK virus | None | Unknown; positive > 4 (after diagnosis) |
| 1287 | MUD | 40 | BK virus | None | Unknown; positive > 4 (after diagnosis) |
| 1352 | HAPLO | 95 | Adv | CTL | 4 |
| 1358 | HAPLO | 86 | CMV | Foscarnet | 12 |
| 1377 | HAPLO | 77 | CMV Parainfluenza | Foscarnet None | 8 3 (after diagnosis) |
UPN indicates unique patient number; CTL, cytotoxic T lymphocyte; MUD, matched unrelated donor; EBV, Epstein-Barr virus; Adv, adenovirus; CMV, cytomegalovirus; VZV, varicella-zoster virus; HSV, herpes simplex virus; and HAPLO, haploidentical donor.